Verastem (FRA:2VSA) Days Payable : 0.00 (As of Mar. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Verastem Days Payable?

Verastem's average Accounts Payable for the three months ended in Mar. 2024 was €6.72 Mil. Verastem's Cost of Goods Sold for the three months ended in Mar. 2024 was €0.00 Mil.

The historical rank and industry rank for Verastem's Days Payable or its related term are showing as below:

During the past 13 years, Verastem's highest Days Payable was 6033.36. The lowest was 62.36. And the median was 1294.34.

FRA:2VSA's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 148.78
* Ranked among companies with meaningful Days Payable only.

Verastem's Days Payable stayed the same from Mar. 2023 (0.00) to Mar. 2024 (0.00). stayed the same

Verastem Days Payable Historical Data

The historical data trend for Verastem's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verastem Days Payable Chart

Verastem Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

1,278.94

67.31

Verastem Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Verastem's Days Payable

For the Biotechnology subindustry, Verastem's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Verastem's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Verastem's Days Payable distribution charts can be found below:

* The bar in red indicates where Verastem's Days Payable falls into.

Verastem Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Verastem's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (4.627	+	6.588)	/	2 )	/	0	*	365
=	5.6075					/	0	*	365
=	N/A

Verastem's Days Payable for the quarter that ended in Mar. 2024 is calculated as:

	Days Payable (Q: Mar. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2023 )	+	Accounts Payable (Q: Mar. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
=	( (6.588	+	6.853)	/	2 )	/	0	*	365 / 4
=	6.7205					/	0	*	365 / 4
=	N/A

Verastem Days Payable Related Terms

Thank you for viewing the detailed overview of Verastem's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Verastem (FRA:2VSA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verastem Inc (FRA:2VSA) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

VSTM:USA 0LOV:UK

Address

117 Kendrick Street, Suite 500, Needham, MA, USA, 02494

Website

https://www.verastem.com

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

Verastem (FRA:2VSA) Headlines

No Headlines